23andMe cut 40% of its workforce and will discontinue its therapeutic program as part of ongoing restructuring. This comes after a data breach, series of layoffs and the resignation of its board members.
A slowdown in China and the US, along with signs of a weaker cough & cold season in the latter, has led Bayer Consumer Health to lower its full-year sales guidance.
Finland is the latest market launch for OTC erectile dysfunction treatment Eroxon. High demand for the product in other countries, such as Norway, helped drive up Navamedic's consumer health sales in the first nine months of 2024.
Opill marketer Perrigo builds on marketing collaboration with WNA in partnership with Napheesa Collier; Bucked Up partners with MMA champion and entrepreneur Conor McGregor; and Recover 180 collaborates with NBA players.
A round-up of recent consumer health appointments: PharmaSGP names new CEO; Stada appoints Vietnam head; NèreS adds to board.
Stada will ship a wide range of consumer healthcare products from its new Romanian production facility, into which the German firm has invested over €70m.
“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.
The International Council for Advertising Self-Regulation has launched a "Global Think Tank" to further effective industry self-regulation in the area of advertising, backed by national authorities such as the UK's ASA.
Although FDA concluded OTC oral phenylephrine is ineffective as a nasal decongestant in doses up to highest studied level, federal preemption precludes challenges to agency’s regulation of labeling for phenylephrine and other Rx and OTC drugs, according to recent decision in New York federal court.
Bayer Consumer Health is replacing mixed material PVC blister packs with monomaterial PET blisters beginning with Aleve in the Netherlands. HBW Insight speaks to vice president and global head of design, packaging, product experience and sustainability, Chris Padain, about the "evolutionary" strategy behind the move, the complexities of choosing the right material for the right product, and the importance of industry cross-collaboration via associations like GSCF.
Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.
Haleon highlighted consistent market share gains in China as it reported third-quarter results.
French public sector investment bank Bpifrance's influence over the future strategy of Opella extends to its one seat on the company's board, but not past that, Sanofi confirms as it reports Q3 results.
Reckitt backs up prediction for strong sales during current quarter with advertising featuring a beauty queen and a line extension for Mucinex, one its strongest US consumer health product lines.
Bayer hopes Impli's implantable hormone biosensor will reveal self-care opportunities in the areas of stress, sleep, weight management, cardiovascular health, women’s health, or bone health.
A better than expected showing from its Health business in its latest quarter has teed up Reckitt for a big finish to the year.
FDA tobacco programs chief emphasizes moving smokers to lower risk alternatives and NIDA executive encourages proposals for e-cigarettes as nicotine replacement treatments. FDA also seizes $76m in unauthorized e-cigarettes.
After coming under fire from French politicians and workers unions over its proposal to sell a majority stake in its consumer health business to US private-equity firm CD&R, Sanofi has invited the French state in on the deal and made a number of binding commitments to jobs and investment.
Kenvue may have to start sharing time with Bausch + Lomb in investors’ discussions about the outlook for success at US consumer health firms separated from former parent firms as they and their competitors begin reporting the results for their latest quarters.
Major Europe-based consumer health players Sanofi, Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2024 results over the coming weeks.